Harbour BioMed opens stock 02142 to qualified mainland investors via Stock Connect

Key Facts

1Harbour BioMed stock 02142 joined Stock Connect through the Shanghai-Hong Kong and Shenzhen-Hong Kong channels.

2An individual investor needs an aggregate balance of at least 500,000 Chinese yuan in securities and cash accounts.

3First-half revenue was 122.5 million dollars, profit for the period was 64.9 million dollars and adjusted net profit was 71.6 million dollars.

Harbour BioMed stock 02142 was added to the eligible securities list for Stock Connect. Qualified mainland investors can now trade it through the Shanghai-Hong Kong and Shenzhen-Hong Kong channels. The release was distributed at 20:01 ET on September 6, 2026, equal to 00:01 UTC and 08:01 in Hong Kong on September 7, 2026. The company expects a broader investor base and better liquidity, but the release reported no actual flows resulting from inclusion.

Southbound Stock Connect links mainland investors to eligible securities in the Hong Kong market. Participation is limited to institutions and individuals that satisfy the eligibility requirements. An individual investor needs an aggregate balance of at least 500,000 Chinese yuan in securities and cash accounts. Inclusion therefore broadens trading access, but it neither issues new shares nor generates operating revenue by itself.

The company announced on August 27, 2026 its results for the 6 months ended June 30, 2026. Revenue was 122.5 million dollars, an increase of 20.9% year over year. Profit for the period was 64.9 million dollars, while adjusted net profit was 71.6 million dollars. Cash and cash equivalents were 359.2 million dollars on June 30, 2026, and adjustments mainly covered share-based compensation and other one-time expenses.

Harbour BioMed develops antibody therapies through internal research, licensing and partnerships. Its first-half results attributed revenue growth to collaborations, product out-licensing and growth at Nona Biosciences. An agreement announced in February 2026 granted Solstice Oncology development and commercialization rights to HBM4003 outside Greater China. The package included 50 million dollars of upfront cash, 5 million dollars of near-term cash and more than 50 million dollars of equity, plus contingent milestones of about 1.1 billion dollars and royalties.

Windward Bio develops HBM9378 as WIN378, a fully human monoclonal antibody targeting TSLP. WIN378 is being evaluated in the Phase 2/3 POLARIS asthma study. The company expects initial data from the Phase 2 portion of POLARIS in the second half of 2026 and the first Phase 3 study to begin in the fourth quarter of 2026. Patient dosing in the Phase 2 SIRIUS study for COPD began in June 2026; these are expected milestones, and stock inclusion is neither approval of WIN378 nor assurance of successful studies.